Kayaker/JDStox:

.

Just wanted to comment on some excerpts from a post made a few days ago in which the following was stated:

.

"As you note, ..."the tumours were not measured at 21 days in any of the mice. (You have to kill the mice to measure that.)...".  You can't know that you reduced the number or size of something if you don't know what you started with."
.

Killing the mice to determine the number of tumours at any given time point is not necessary.  Reference the following document:

.

http://www.transonc.com/pdf/manuscript/v05i03/neo12109.pdf

.

Briefly, the document demonstrates that invivo imaging is done via a 3D MRI with the particular cancer cell lines transfected with enhanced green flourescence protein.  As the document states, the imaging was done at various time points and the number of tumours counted at each.  The flourescent tagged cancer cells light up the MRI image and you can measure tumour size, location, numbers etc.  In fact, TTU would have done this as well to determine if the cell lines had  metastasised to the brain. Don't know if they did all the mice or not, but they certainly would have done some random imaging.

.

The press release doesn't state a number of items, such as the number of cancer cells injected, imaging done at 21 days or any other days for that matter etc. etc.  There are a number of assumptions made based on previous science at TTU as it relates to the treatment model.  This would probably include what to expect at various time points for tumour numbers, size, growth rates etc.  Dr. Wilf Jeffries commentary is relevant as it relates to this:

.

“The treatment model that Dr. Lockman and his team have developed at Texas Tech is at the leading edge of research for assessing drug therapies for metastatic brain cancer. The highly statistically significant reductions in the number and size of HER2+ metastatic breast cancer tumors due to BT2111 treatment that biOasis is reporting today forms part of a massive and rigorous effort to assess the potential of Transcend Conjugates to traverse the blood-brain barrier and treat diseases of the brain,” said Dr. Wilf Jefferies, inventor of the Transend technology and Founding Scientist of biOasis.

.

From my understanding, this model is not only used by TTU, but also used by agencies such as the NIH.  I guess we could take biOasis to task for not including every detail in the PR and perhaps not taking "us investors into account", but when Dr. Wilf Jeffries says:  "The highly statistically significant reductions in the number and size of HER2+ metastatic breast cancer tumours due to BT2111 treatment", I think I'll take him at his word.

.

Secondly, just wanted to comment on the following:

.

"As you state, "...there is no evidence in the biOasis press release that the BT2111 mice had fewer tumours (or tumour cells or tumour volume) at 35 days than they had at 21 days.  What they had was fewer tumours than the untreated mice had...""
.

One needs to look at the excerpts from previous biOasis press releases as they relate to the work done at BC Cancer and the ADCC assay.  Both of these previous work programs concluded the following:

.

"In several HER2+ breast cancer cell lines, BT2111 demonstrated a significant improvement in cancer killing activity compared to trastuzumab alone."

.

When you combine the evidence of previous work programs, it seems that there is evidence of fewer tumours, tumour cells or tumour volume. 

.

Thirdly, just some commentary on the following:

"One other point in your blog.  You state "...it's not a stretch to say that BT2111 could entirely replace Herceptin in the marketplace...".  I've seen that suggestion before but can't say that I understand it."

.

BT2111 has shown that there is a significant improvement in cancer killing over trastuzumab and we know that cancer cell lines over time become drug resistant.  It's all about hitting HER2+ cancer (or any cancer for that matter) as hard as you can out of the gate before these issues start to arise.  If patients can tolerate the dose, if side effects can me managed, maximum dosage is probably the route and that would point to BT2111 as a standard of care vs. Herceptin.